

# Interpace Diagnostics Group

12:50 19 Jul 2018

## Interpace Diagnostics Group expands application of its cancer pathology test PancaGEN

Interpace Diagnostics Group (NASDAQ:IDYG) has expanded the application of its pathology test PancaGEN beyond its use to see whether pancreatic cysts are cancerous to include bile duct strictures and solid pancreatic lesions.

PancaGEN is a DNA-based molecular pathology test that assesses the risk of cancer in pancreatic cysts.

The widening of PancaGEN's application to include the detection of cancer in solid pancreatic and bile duct lesions is based on new guidelines that have come out, as well as a raft of recent clinical studies.

Indeed, the most recent National Comprehensive Cancer Network guidelines for Hepatobiliary cancers recommend molecular testing in patients who are suffering from bile duct obstruction or other abnormalities in order to diagnose bile duct cancer. The American College of Gastroenterology guidelines for the management of the management of primary sclerosing cholangitis, a chronic liver disease, also suggest the introduction of molecular testing to exclude a diagnosis of bile duct cancer.

Three new peer-reviewed papers written about research conducted at Columbia University, Washington University and the Arizona Center for Digestive Health support the use of PancaGEN for detecting cancer in bile duct strictures and solid pancreatic lesions as well.

"We are pleased to see the updated NCCN guidelines and the multiple peer-reviewed papers that further support the use of molecular diagnostics in assessing the potential for pancreatic and bile duct cancers across a more expansive patient population," said Jack Stover, CEO of Interpace, in a statement.


PancaGEN is 90% accurate according to clinical studies. Pancreatic cancer is difficult to diagnose in early stages and spreads rapidly, with symptoms surfacing when the cancer is advanced.

Interpace's shares were flat in afternoon trade at US\$1.02.

**Price:** 4.1

**Market Cap:** \$16.57 m

### 1 Year Share Price Graph



January 2020 July 2020 January 2021

### Share Information

**Code:** IDYG

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	10.98	2.58

**Sector:**

**Website:**

### Company Synopsis:

Interpace Diagnostics develops molecular diagnostic tests. You can be assured that all of the molecular tests we offer are driven by rigorous, validated science. We power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.